Evidence map›Paper›PMID 35897644›Full record

ArticleInternational journal of molecular sciences2022

Lipoprotein Profile in Immunological Non-Responders PLHIV after Antiretroviral Therapy Initiation.

Jenifer Masip, Rosa Jorba, Miguel López-Dupla, Pere Domingo, Yolanda María Pacheco, Graciano García-Pardo, Esteban Martínez, Consuelo Viladés, Sergi Veloso, Verónica Alba and 5 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Lipid metabolism, microglia, and stroke.Neural regeneration research · 2026
    Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Jenifer MasipInfection and Immunity Research Group (INIM), Universitat Rovira i Virgili, 43003 Tarragona, Spain.
Rosa JorbaInfection and Immunity Research Group (INIM), Universitat Rovira i Virgili, 43003 Tarragona, Spain.ORCID 0000-0003-3307-4340
Miguel López-DuplaInfection and Immunity Research Group (INIM), Universitat Rovira i Virgili, 43003 Tarragona, Spain.ORCID 0000-0002-9141-2523
Pere DomingoInfectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.ORCID 0000-0003-1138-5770
Yolanda María PachecoImmunology Lab, Institute of Biomedicine of Seville, University Hospital Virgen del Rocío/CSIC/University of Seville, 41013 Seville, Spain.
Graciano García-PardoInfection and Immunity Research Group (INIM), Universitat Rovira i Virgili, 43003 Tarragona, Spain.
Esteban MartínezCentro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.
Consuelo ViladésInfection and Immunity Research Group (INIM), Universitat Rovira i Virgili, 43003 Tarragona, Spain.
Sergi VelosoInfection and Immunity Research Group (INIM), Universitat Rovira i Virgili, 43003 Tarragona, Spain.
Verónica AlbaInfection and Immunity Research Group (INIM), Universitat Rovira i Virgili, 43003 Tarragona, Spain.
Montserrat OlonaInfection and Immunity Research Group (INIM), Universitat Rovira i Virgili, 43003 Tarragona, Spain.
Francesc VidalInfection and Immunity Research Group (INIM), Universitat Rovira i Virgili, 43003 Tarragona, Spain.
Frederic Gómez-BertomeuInfection and Immunity Research Group (INIM), Universitat Rovira i Virgili, 43003 Tarragona, Spain.
Joaquim PeraireInfection and Immunity Research Group (INIM), Universitat Rovira i Virgili, 43003 Tarragona, Spain.
Anna RullInfection and Immunity Research Group (INIM), Universitat Rovira i Virgili, 43003 Tarragona, Spain.ORCID 0000-0002-8907-7754
Instituto de Salud Carlos III · ESInstitut de Recerca Biomèdica Catalunya Sud · ESHospital de Sant Pau · ESInstituto de Biomedicina de Sevilla · ES

Funding

Government of Catalonia AGAUR 2021SGRInstitut d'Investigació Sanitària Pere Virgili 2019/IISPV/05Instituto de Salud Carlos III PI16/00503;PI19/01337;PI20/00326;RD16/0025/0006;CB21/13/00020;INT20/00031;CP19/00146Rovira i Virgili University 2019PMF-PIPF-18
6 · The paper itself

Abstract

Nuclear magnetic resonance (NMR)-based advanced lipoprotein tests have demonstrated that LDL and HDL particle numbers (LDL-P and HDL-P) are more powerful cardiovascular (CV) risk biomarkers than conventional cholesterol markers. Of interest, in people living with HIV (PLHIV), predictors of preclinical atherosclerosis and vascular dysfunction may be associated with impaired immune function. We previously stated that immunological non-responders (INR) were at higher CV risk than immunological responders (IR) before starting antiretroviral therapy (ART). Using Liposcale

Indexed as

Anti-HIV AgentsAtherosclerosisHIV InfectionsBiomarkersCholesterolHumansLipoproteinsAnti-HIV AgentsBiomarkersCholesterolLipoproteinsantiretroviral therapycardiovascular riskimmunological non-responderlipoproteinslongitudinal analysisnuclear magnetic resonancepeople living with HIV

Identifiers

PMID35897644
PMCPMC9330003
OpenAlexW4286587662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.